Head to Head Comparison: MariMed (OTCMKTS:MRMD) versus Envista (NYSE:NVST)

MariMed (OTCMKTS:MRMD) and Envista (NYSE:NVST) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Earnings and Valuation

This table compares MariMed and Envista”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MariMed	$159.83 million	0.14	-$14.48 million	($0.04)	-1.40
Envista	$2.72 billion	1.37	$47.00 million	$0.58	39.92

Envista has higher revenue and earnings than MariMed. MariMed is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for MariMed and Envista, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MariMed	0	2	0	0	2.00
Envista	0	11	6	0	2.35

Envista has a consensus target price of $28.86, suggesting a potential upside of 24.63%. Given Envista’s stronger consensus rating and higher probable upside, analysts plainly believe Envista is more favorable than MariMed.

Risk & Volatility

MariMed has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, Envista has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.

Insider & Institutional Ownership

0.2% of MariMed shares are owned by institutional investors. 16.1% of MariMed shares are owned by company insiders. Comparatively, 1.0% of Envista shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares MariMed and Envista’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MariMed	-9.13%	-10.71%	-2.58%
Envista	3.33%	7.88%	4.33%

Summary

Envista beats MariMed on 10 of the 13 factors compared between the two stocks.

About MariMed

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty’s Eddies brand and ice creams under Emack & Bolio’s brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.